Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases

• Published in: Leukemia & lymphoma Vol. 60; no. 2; pp. 471 - 476
• Main Authors: Jurczyszyn, Artur, Davila, Julio, Kortüm, K. Martin, Jayabalan, David S., Vij, Ravi, Fiala, Mark, Milunovic, Vibor, Chim, C.S., Wiśniewska-Piąty, Katarzyna, Waszczuk-Gajda, Anna, Crusoe, Edvan, Hajek, Roman, Robak, Paweł, Raźny, Małgorzata, Zawirska, Daria, Bittrich, Max, Nahi, Hareth, Liu, Jieqi, Castillo, Jorge J., Vesole, David H.
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 28.01.2019
• Subjects: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Child; Combined Modality Therapy; Cytogenetic Analysis; Disease Management; Early-onset multiple myeloma; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Medicin och hälsovetenskap; Multiple Myeloma - diagnosis; Multiple Myeloma - epidemiology; Multiple Myeloma - etiology; Multiple Myeloma - therapy; Outcome Assessment, Health Care; Patient Selection; prognosis; Retrospective Studies; survival; Treatment Outcome; treatment response; Young Adult; Early-onset multiple myeloma; prognosis; treatment response; survival
• ISSN: 1042-8194; 1029-2403; 1029-2403
• DOI: 10.1080/10428194.2018.1480766

A small proportion of patients with multiple myeloma (MM) are diagnosed at a very young age. The clinicopathological characteristics and prognosis of these patients are not well known. This analysis included 52 patients diagnosed with MM at the age of ≤30 years (range: 8-30 years). 68% of patients had International Scoring System (ISS) 1 MM; 22% presented with the light chain-only disease, and 48% with elevated serum lactate dehydrogenase (LDH). 85% of patients were treated with novel agents, and 62% received front-line autologous stem cell transplantation (ASCT). Overall response rate (ORR) to front-line treatment and ASCT were 71% and 90%, respectively. The group was followed-up for the median period of 86 months. The median overall survival (OS) was 166 months (95% CI: 53-222), with 5-year OS rate of 77% (95% CI: 61.0-87.9). This findings suggest that the prognosis in young MM patients may be as good if not better than in the general population of MM patients.